title: The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A.
authors.affiliation: Department of Surgery, Free University of Berlin, Germany.
authors.forename: A R
authors.initials: AR
authors.lastname: Mueller
authors.forename: K P
authors.initials: KP
authors.lastname: Platz
authors.forename: G
authors.initials: G
authors.lastname: Blumhardt
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: T
authors.initials: T
authors.lastname: Steinmüller
authors.forename: W
authors.initials: W
authors.lastname: Christe
authors.forename: U
authors.initials: U
authors.lastname: Hopf
authors.forename: H
authors.initials: H
authors.lastname: Lobeck
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000208:Acute Disease; D016572:Cyclosporine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016903:Drug Monitoring; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D016572:Cyclosporine; D016559:Tacrolimus